DrugPatentWatch Database Preview
Spil Company Profile
What is the competitive landscape for SPIL, and when can generic versions of SPIL drugs launch?
SPIL has two approved drugs.
There are two US patents protecting SPIL drugs.
Summary for Spil
| US Patents: | 2 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-001 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-003 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-001 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-002 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-002 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-004 | Jan 26, 2018 | RX | Yes | Yes | 9,504,655 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-004 | Jan 26, 2018 | RX | Yes | Yes | 9,700,530 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2954474 | ➤ Sign Up |
| Mexico | 2017000384 | ➤ Sign Up |
| European Patent Office | 3166599 | ➤ Sign Up |
| Japan | 2017523164 | ➤ Sign Up |
| Australia | 2015287299 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2016005934 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 11/016 | Ireland | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| C/GB11/015 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 12/048 | Ireland | ➤ Sign Up | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| C/GB11/013 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| C/GB01/006 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
